Evidence map›Paper›PMID 35614939›Full record

ArticleFrontiers in pharmacology2022

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.

Chuangzhen Lin, Bingqing Yu, Lixin Chen, Zhaohui Zhang, Weixiang Ye, Hui Zhong, Wenke Bai, Yuping Yang, Biao Nie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chuangzhen LinDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Bingqing YuDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Lixin ChenDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Zhaohui ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Weixiang YeDepartment of Gastrointestinal Endoscopy of Dongpu Branch, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Hui ZhongDepartment of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wenke BaiDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Yuping YangDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
Biao NieDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China.
First Affiliated Hospital of Jinan University · CNNanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

farnesoid X receptor (FXR)hepatic fibrosisinterleukin -1βnonalcoholic fatty liver disease (NAFLD)obeticholic acid (OCA)

Identifiers

PMID35614939
PMCPMC9124937
OpenAlexW4229371145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.